ATE519763T1 - Pyrrolopyrazin-kinasehemmer - Google Patents

Pyrrolopyrazin-kinasehemmer

Info

Publication number: ATE519763T1
Authority: AT; Austria
Prior art keywords: kinase inhibitors; pyrrolopyrazine; pyrrolopyrazine kinase; inhibitors; kinase
Prior art date: 2008-02-25

Application number

AT09714560T

Other languages

English (en)

Inventor

Bois Daisy Du

Todd Elworthy

Robert HENDRICKS

Johannes Hermann

Rama KONDRU

Yan Lou

Timothy Owens

Jaehyeon Park

David Smith

Michael Soth

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-25

Filing date

2009-02-16

Publication date

2011-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40514045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE519763(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE519763T1 publication Critical patent/ATE519763T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT09714560T 2008-02-25 2009-02-16 Pyrrolopyrazin-kinasehemmer ATE519763T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3103508P	2008-02-25	2008-02-25
US14651409P	2009-01-22	2009-01-22
PCT/EP2009/051759 WO2009106444A1 (en)	2008-02-25	2009-02-16	Pyrrolopyrazine kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE519763T1 true ATE519763T1 (de)	2011-08-15

Family

ID=40514045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09714560T ATE519763T1 (de)	2008-02-25	2009-02-16	Pyrrolopyrazin-kinasehemmer

Country Status (18)

Country	Link
US (1)	US8119636B2 (de)
EP (1)	EP2247593B1 (de)
JP (1)	JP5284377B2 (de)
KR (1)	KR20100114095A (de)
CN (1)	CN101952296B (de)
AR (1)	AR070467A1 (de)
AT (1)	ATE519763T1 (de)
AU (1)	AU2009218609A1 (de)
BR (1)	BRPI0907928A2 (de)
CA (1)	CA2713718A1 (de)
CL (1)	CL2009000405A1 (de)
IL (1)	IL206818A0 (de)
MX (1)	MX2010009023A (de)
PE (1)	PE20091738A1 (de)
RU (1)	RU2010139284A (de)
TW (1)	TW200942543A (de)
WO (1)	WO2009106444A1 (de)
ZA (1)	ZA201004942B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101945877B (zh) *	2008-02-25	2013-07-03	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
CA2712507A1 (en) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
KR20170015566A (ko)	2008-11-10	2017-02-08	버텍스 파마슈티칼스 인코포레이티드	Ａｔｒ 키나제의 억제제로서 유용한 화합물
CN102300862B (zh)	2008-12-19	2016-11-23	沃泰克斯药物股份有限公司	用作atr激酶抑制剂的化合物
US8518945B2 (en) *	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
JP5836367B2 (ja)	2010-05-12	2015-12-24	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143422A1 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	2 -aminopyridine derivatives useful as inhibitors of atr kinase
US9062008B2 (en)	2010-05-12	2015-06-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
JP2013526539A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用なピラジン
US8969356B2 (en)	2010-05-12	2015-03-03	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
KR20130083386A (ko) *	2010-05-20	2013-07-22	에프. 호프만-라 로슈 아게	피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
CN102906095A (zh) *	2010-05-20	2013-01-30	弗·哈夫曼-拉罗切有限公司	作为syk和jak抑制剂的吡咯并吡嗪衍生物
WO2011163527A1 (en)	2010-06-23	2011-12-29	Vertex Pharmaceuticals Incorporated	Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
CA2832100A1 (en)	2011-04-05	2012-10-11	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of tra kinase
MX2013013331A (es) *	2011-05-17	2014-10-17	Principia Biopharma Inc	Derivados de azaindol como inhibidores de tirosina-cinasas.
EP2723746A1 (de)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Als art-kinasehemmer nützliche verbindungen
US9096602B2 (en)	2011-06-22	2015-08-04	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
EP2723745A1 (de)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Als art-kinasehemmer nützliche verbindungen
MX359032B (es) *	2011-09-01	2018-09-12	Hoffmann La Roche	Inhibidores de pirrolopirazina cinasa.
EP2751088B1 (de)	2011-09-30	2016-04-13	Vertex Pharmaceuticals Incorporated	Als atr-kinasehemmer nützliche verbindungen
CA2850491C (en)	2011-09-30	2020-10-27	Vertex Pharmaceuticals Incorporated	Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors
US8853217B2 (en)	2011-09-30	2014-10-07	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (de)	2011-09-30	2015-08-21	Vertex Pharma
CA2850566C (en)	2011-09-30	2022-05-03	Vertex Pharmaceuticals Incorporated	Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
WO2013064445A1 (en)	2011-11-01	2013-05-10	F. Hoffmann-La Roche Ag	Imidazopyridazine compounds
WO2013071093A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Pyrazine compounds useful as inhibitors of atr kinase
EP2776419B1 (de)	2011-11-09	2016-05-11	Vertex Pharmaceuticals Incorporated	Pyrazin verbindungen als atr kinase inhibitoren
WO2013071094A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776421A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Als atr-kinasehemmer nützliche verbindungen
EP2776422A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Als atr-kinasehemmer nützliche verbindungen
RU2627661C2 (ru)	2012-01-10	2017-08-09	Ф. Хоффманн-Ля Рош Аг	Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk)
SI2833973T1 (en)	2012-04-05	2018-04-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase and their combination therapy
US9334278B2 (en) *	2012-08-21	2016-05-10	Hoffmann-La Roche Inc.	Pyrrolo[2,3-B]pyrazines as SYK inhibitors
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (de)	2012-10-16	2015-08-26	Vertex Pharmaceuticals Incorporated	Als atr-kinaseinhibitoren nützliche verbindungen
KR102213986B1 (ko)	2012-12-07	2021-02-09	버텍스 파마슈티칼스 인코포레이티드	Atr 키나제의 억제제로서 유용한 화합물
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
WO2014186101A1 (en) *	2013-05-14	2014-11-20	3M Innovative Properties Company	Pyridine- or pyrazine-containing compounds
CN105934435B (zh)	2013-12-06	2019-02-22	沃泰克斯药物股份有限公司	用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
CN110590787A (zh)	2014-06-05	2019-12-20	沃泰克斯药物股份有限公司	Atr激酶抑制剂的制备方法及其不同的固体形式
EP3157566B1 (de)	2014-06-17	2019-05-01	Vertex Pharmaceuticals Incorporated	Verfahren zur behandlung von krebs mit einer kombination aus chk1- und atr-inhibitoren
CA3000684A1 (en)	2015-09-30	2017-04-06	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US20170100396A1 (en)	2015-10-07	2017-04-13	F. Hoffmann-La Roche Ag	Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
AU2020405536B2 (en)	2019-12-20	2023-09-07	Pfizer Inc.	Benzimidazole derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ301750B6 (cs)	1999-12-24	2010-06-09	Aventis Pharma Limited	Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
KR20040111445A (ko)	2002-03-28	2004-12-31	에자이 가부시키가이샤	신경퇴행성 질환 치료용 ｃ─ＪｕｎＮ─말단 키나아제억제제로서의 ７─아자인돌
EP1696920B8 (de) *	2003-12-19	2015-05-06	Plexxikon Inc.	Verbindungen und verfahren zur entwicklung von ret-modulatoren
CA2587894A1 (en) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US7456289B2 (en) *	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) *	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es)	2006-12-21	2012-08-24	Plexxikon Inc	Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CA2712507A1 (en) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
PT2247592E (pt) *	2008-02-25	2011-11-03	Hoffmann La Roche	Inibidores de pirrolpirazina-cinase

2009
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Application Discontinuation
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-16 EP EP09714560A patent/EP2247593B1/de not_active Not-in-force
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en active Application Filing
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown

Also Published As

Publication number	Publication date
BRPI0907928A2 (pt)	2015-07-28
EP2247593B1 (de)	2011-08-10
RU2010139284A (ru)	2012-04-10
CL2009000405A1 (es)	2010-02-26
KR20100114095A (ko)	2010-10-22
US20090215785A1 (en)	2009-08-27
TW200942543A (en)	2009-10-16
PE20091738A1 (es)	2009-11-13
AR070467A1 (es)	2010-04-07
ZA201004942B (en)	2011-12-28
US8119636B2 (en)	2012-02-21
CN101952296A (zh)	2011-01-19
IL206818A0 (en)	2010-12-30
MX2010009023A (es)	2010-09-07
WO2009106444A1 (en)	2009-09-03
AU2009218609A1 (en)	2009-09-03
EP2247593A1 (de)	2010-11-10
JP2011513263A (ja)	2011-04-28
JP5284377B2 (ja)	2013-09-11
CN101952296B (zh)	2013-08-21
CA2713718A1 (en)	2009-09-03

Publication	Publication Date	Title
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
DK2247592T3 (da)	2011-09-26	Pyrrolopyrazinkinaseinhibitors
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
CY2019009I1 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
EP2278969A4 (de)	2011-10-05	Januskinase-hemmer
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
EP2498607A4 (de)	2013-06-19	Kinase-inhibitoren
EP2493313A4 (de)	2013-05-15	Kinase-inhibitoren
BRPI0922962A2 (pt)	2019-09-24	inibidores de p38 map quinase
DK2350047T3 (da)	2013-09-30	p38-MAP-KINASEINHIBITORER
EP2558099A4 (de)	2013-07-17	Kinase-inhibitoren
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
EP2310384A4 (de)	2012-02-22	Januskinase-hemmer
BRPI0912475A8 (pt)	2018-03-20	compostos como inibidores de quinase
BRPI0918564A2 (pt)	2015-12-01	inibidores
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
EP2231152A4 (de)	2011-06-08	Thienopyranone als kinasehemmer
BRPI0912564A2 (pt)	2019-09-24	inibidores de jnk

Legal Events

Date	Code	Title	Description
2012-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties